TrippBio, a biotechnology company, is producing a patent-pending repurposed FDA-approved drug called TD213 intended for the treatment of viral infections, initially targeting COVID-19, it was reported on Monday.
TD213 is administered orally twice daily and works by halting the SARS-CoV-2 virus and the associated acute inflammatory response to the infection.
The firm has revealed positive interim data from the investigator-initiated study to evaluate the efficacy of the product in treating patients with confirmed mild-moderate COVD-19.
Dr Moti N. Ramgopal of Midway Immunology and Research Center conducted the study. Outpatients who tested positive using a validated SARS-CoV-2 RNA COVID-19 test were administered the product twice daily for 14 days and will be followed until day 28.
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
LabGenius and Sanofi launch AI-driven collaboration on antibody optimisation
Mitsubishi Tanabe Pharma America changes name
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
Xenogenic Materials Demonstrate Promising Results in Peri-Implantitis Management
European Commission approves Celltrion's Remsima IV liquid formulation
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
Henlius and Organon secure first US approval for pertuzumab biosimilar POHERDY